FRAMINGHAM, Mass.--Genzyme Molecular Oncology here and Bayer have inked an agreement that will allow Bayer the use of Genzyme Molecular Oncology's patented Serial Analysis of Gene Expression (SAGE) technology.
Bayer will utilize SAGE to identify genes that may have importance in drug development. Financial terms of the agreement were not disclosed.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
